The 5-Hydroxytryptamine Receptor 1B pipeline drugs market research report outlays comprehensive information on the 5-Hydroxytryptamine Receptor 1B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the 5-Hydroxytryptamine Receptor 1B pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Central Nervous System, Oncology, Mouth and Dental Disorders, and Cardiovascular which include the indications Migraine, Cluster Headache Syndrome (Cluster Headache), Lymphoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Mouth and Dental Disorders, and Pulmonary Arterial Hypertension. It also reviews key players involved in 5-Hydroxytryptamine Receptor 1B targeted therapeutics development with respective active and dormant or discontinued products.
The 5-Hydroxytryptamine Receptor 1B pipeline targets constitutes close to 18 molecules. Out of which, approximately 17 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, and Preclinical stages are 2, 1, 1, 3, 3, 1, and 6 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
5-Hydroxytryptamine Receptor 1B overview
5-hydroxytryptamine receptor 1B (HTR1B) is a G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.
For a complete picture of 5-Hydroxytryptamine Receptor 1B’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.